• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Pfizer

Pfizer

Pfizer Inc PFE 3 Star

Last Price$34.47Day Change (%)-0.49%
Open Price$34.73Day Change ($)-0.17
Day Range34.40–34.8152-Week Range27.51–34.97

As of Fri 3/5/2015 8:09:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Targacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company

    Targacept and Catalyst Biosciences Enter Definitive Merger Agreement Creating a Protease-Based Hemostasis and Anti-Complement Company

  2. Biotech Bidding War Yields Rich Price

    Biotech Bidding War Yields Rich Price

  3. Lieff Cabraser Joins Over Three Hundred And Seventy Businesses In Support Of Marriage Equality

    Lieff Cabraser Joins Over Three Hundred And Seventy Businesses In Support Of Marriage Equality

  4. Research and Markets: Hyperlipidemia Pipeline Review 2015 - Featuring 25 Leading Companies

    Research and Markets: Hyperlipidemia Pipeline Review 2015 - Featuring 25 Leading Companies

  5. Research and Markets: Anaplastic Large Cell Lymphoma (ALCL) Pipeline Review 2015 - 9 Companies & 12 Drug Profiles

    Research and Markets: Anaplastic Large Cell Lymphoma (ALCL) Pipeline Review 2015 - 9 Companies & 12 Drug Profiles

  6. Research and Markets: Myelofibrosis Pipeline Review 2015 - 18 Companies & 23 Drug Profiles

    Research and Markets: Myelofibrosis Pipeline Review 2015 - 18 Companies & 23 Drug Profiles

  7. Research and Markets: Global Smoking Cessation Pipeline Review 2015 - 16 Companies & 23 Drug Profiles

    Research and Markets: Global Smoking Cessation Pipeline Review 2015 - 16 Companies & 23 Drug Profiles

  8. Research and Markets: Global Alcohol Addiction Therapeutics Pipeline Review 2015 - 23 Companies 35 Drug Profiles

    Research and Markets: Global Alcohol Addiction Therapeutics Pipeline Review 2015 - 23 Companies 35 Drug Profiles

  9. Pfizer May Go Shopping for Growth

    Despite an improving pipeline and slowing patent losses, a lackluster growth outlook will likely drive Pfizer to acquire assets in the near term.

  10. Pfizer Files 8K - Entry Into Definitive Agreement

    Pfizer Files 8K - Entry Into Definitive Agreement

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.